The tolerability of efavirenz after nevirapine-related adverse events

Clinical Infectious Diseases

Volumn 31, Issue 3, 2000, Pages 806-807

  Clarke, Susan ^a   Harrington, Patricia ^a   Barry, Michael ^a   Mulcahy, Fiona ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG ABUSE; DRUG INDUCED DISEASE; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; RASH; SIDE EFFECT;

ADULT; AGED; ANTI-HIV AGENTS; ANXIETY DISORDERS; FEMALE; HIV; HIV INFECTIONS; HOMOSEXUALITY; HUMANS; MALE; MIDDLE AGED; NEVIRAPINE; OXAZINES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0034458431     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/314026     Document Type: Article

References (6)

1. Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society-USA Panel
2. High-dose nevirapine: Safety, pharmacokinetics, and antiviral effect in patients with human immuno-deficiency virus infection
3. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial
4. Efficacy of efavirenz-containing regimens in patients with baseline plasma HIV-RNA viral loads exceeding 100,000 copies/mL
5. Antiretroviral drug resistance testing in adults with HIV infection